Request for Covid-19 Impact Assessment of this Report
Market Dynamics
The rapidly growing demand for personalized medicine, R&D expenditure, technological advancements, and increased funding for proteomics projects are prime drivers for automation in the proteomics market. Moreover, need for consistency in quality and a high cost of error also act as growth drivers.
Lack of planning for technology development, low priority for lab automation among small and medium-sized laboratories and high initial setup cost put constraints on the market.
Market Segmentation
The global lab automation market is segmented by equipment and software (automated liquid handling, microplate readers, standalone robots, software and informatics, ASRS), by applications (clinical diagnostics, drug discovery, genomics solutions, proteomics solutions), by type of automation (modular automation and total lab automation), by end users (biotech and pharma, hospitals and private labs, academics and research institutes).
Geographic Analysis
North America and Europe lead the global lab automation in proteomics market along with Canada and Japan. Asia - Pacific and Latin American countries represent emerging markets.
Key Players
Some of the major players in the market include Gilent Technologies Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Danaher Corporation, GE Healthcare, Luminex Corporation, Merck, PerkinElmer Inc., Thermo Fisher Scientific, Inc. and Waters Corporation.
The report contains comprehensive analysis on:
--> Lab Automation in Proteomics Market Segments
--> Lab Automation in Proteomics Market Drivers, Restraints and Opportunities
--> Lab Automation in Proteomics Market Size & Forecast 2016 to 2022
--> Supply & Demand Value Chain
--> Lab Automation in Proteomics Market Current Trends
--> Competition & Major Companies
--> Technology and R&D Status
--> Porters Five Force Analysis
--> Strategic and Critical Success Factor Analysis of Key Players
Regional analysis for Proteomics Market includes
--> North America
>> US and Canada
--> Latin America
>> Mexico, Brazil, Argentina and Rest of Latin America
--> Western Europe
>> EU5 (Germany, France, Italy, Spain, U.K.)
>> Nordic Countries (Denmark, Finland, Norway, and Sweden)
>> Benelux (Belgium, The Netherlands, and Luxembourg)
>> Rest of Western Europe
--> Eastern Europe
>> Russia
>> Poland
>> Rest of Eastern Europe
--> Asia Pacific
>> China
>> India
>> Japan
>> Australia and New Zealand
>> Rest of Asia Pacific
--> Middle East and Africa
>> GCC countries (Saudi Arabia, Oman, Qatar, Bahrain, UAE and Kuwait)
>> South Africa
>> North Africa
>> Rest of Middle East and Africa
This report is an elaborate aggregation of primary inputs from industry experts and participants across the supply chain. It provides in-depth market segmentation that is derived from extensive product mapping exercises, macro-economic factors and other qualitative and quantitative insights. The impact of all such factors are delivered across multiple market segments and geographies.
Report Highlights::
--> Detailed Historical Overview (Market Origins, Product Launch Timeline, etc.)
--> Consumer and Pricing Analysis
--> Market dynamics of the industry
--> In-depth Market Segmentation
--> Historical and Projected Market Sizing in terms of volume and value
--> Recent market trends and Impact Factors
--> R&D Status and Technology Overview
--> Extensive Industry Structure Coverage
Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to rea...
Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in th...
The pharmaceutical agents that are administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs. The global orphan drugs market accounted for $106 billion in 2015, and is anticipated to reach $169 billio...